

DAFTAR PUSTAKA

1. Feder RS, Berdy GJ, Iuorno JD, et al. External Disease and Cornea. In: *2024-2025 BCSC Basic and Clinical Science Course*. American Academy of Ophthalmology; 2024.
2. Dua HS, Ting DSJ, Al Saadi A, Said DG. Chemical eye injury: pathophysiology, assessment and management. *Eye (Basingstoke)*. Springer Nature. 2020;34(11):2001-2019. doi:10.1038/s41433-020-1026-6
3. Vanhoy TBMHPB. chemical burn. *StatPearls [Internet] Treasure Island (FL)*. Published online 2023:1.
4. Soleimani M, Naderan M. Management strategies of ocular chemical burns: Current perspectives. *Clinical Ophthalmology*. Dove Medical Press Ltd. 2020;14:2687-2699. doi:10.2147/OPHTH.S235873
5. Said DG, Dua HS. Chemical burns acid or alkali, what's the difference? *Eye (Basingstoke)*. Springer Nature. 2020;34(8):1299-1300. doi:10.1038/s41433-019-0735-1
6. Zhou H, Zhang W, Bi M, Wu J. The molecular mechanisms of action of PPAR-agonists in the treatment of corneal alkali burns (Review). *Int J Mol Med*. Spandidos Publications. 2016;38(4):1003-1011. doi:10.3892/ijmm.2016.2699
7. Baradaran-Rafii A, Eslani M, Haq Z, Shirzadeh E, Huvard MJ, Djalilian AR. Current and Upcoming Therapies for Ocular Surface Chemical Injuries. *Ocular Surface*. Elsevier Inc. 2017;15(1):48-64. doi:10.1016/j.jtos.2016.09.002
8. Tenório MCDS, Graciliano NG, Moura FA, de Oliveira ACM, Goulart MOF. N-acetylcysteine (Nac): Impacts on human health. *Antioxidants*. MDPI. 2021;10(6). doi:10.3390/antiox10060967
9. Santus P, Signorello JC, Danzo F, Lazzaroni G, Saad M, Radovanovic D. Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective. *J Clin Med*. Multidisciplinary Digital Publishing Institute (MDPI). 2024;13(14). doi:10.3390/jcm13144127
10. Tieu S, Charchoglyan A, Paulsen L, et al. N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals. *Antioxidants*. Multidisciplinary Digital Publishing Institute (MDPI). 2023;12(10). doi:10.3390/antiox12101867
11. Kubota M, Shimmura S, Kubota S, et al. Hydrogen and N-Acetyl-L-Cysteine Rescue Oxidative Stress-Induced Angiogenesis in a Mouse Corneal Alkali-Burn Model. 2011;52:427-433. doi:10.1167/iovs.10
12. Gujral GS, Askari SN, Ahmad S, Zakir SM, Saluja K. Topical vitamin C, vitamin E, and acetylcysteine as corneal wound healing agents: A comparative study. *Indian J Ophthalmol*. 2020;68(12):2935-2939. doi:10.4103/ijo.IJO_1463_20

13. Eghtedari Y, Oh LJ, Girolamo N Di, Watson SL. The role of topical N-acetylcysteine in ocular therapeutics. *Surv Ophthalmol.Elsevier Inc.* 2022;67(2):608-622. doi:10.1016/j.survophthal.2021.07.008
14. Jhanji V, Billig I, Yam GHF. Cell-Free Biological Approach for Corneal Stromal Wound Healing. *Front Pharmacol.Frontiers Media S.A.* 2021;12. doi:10.3389/fphar.2021.671405
15. Wilson SE. Corneal wound healing. *Exp Eye Res.* 2020;197. doi:10.1016/j.exer.2020.108089
16. Saghizadeh M, Kramerov AA, Svendsen CN, Ljubimov A V. Concise Review: Stem Cells for Corneal Wound Healing. *Stem Cells.* 2017;35(10):2105-2114. doi:10.1002/stem.2667
17. Loureiro RR, Gomes JÁP. Biological modulation of corneal epithelial wound healing. *Arq Bras Oftalmol.Conselho Brasileiro De Oftalmologia.* 2019;82(1):78-84. doi:10.5935/0004-2749.20190016
18. Mobaraki M, Abbasi R, Vandchali SO, Ghaffari M, Moztarzadeh F, Mozafari M. Corneal repair and regeneration: Current concepts and future directions. *Front Bioeng Biotechnol.Frontiers Media S.A.* 2019;7(JUN). doi:10.3389/fbioe.2019.00135
19. Ljubimov A V., Saghizadeh M. Progress in corneal wound healing. *Prog Retin Eye Res.Elsevier Ltd.* 2015;49:17-45. doi:10.1016/j.preteyeres.2015.07.002
20. Bukowiecki A, Hos D, Cursiefen C, Eming SA. Wound-healing studies in cornea and skin: Parallels, differences and opportunities. *Int J Mol Sci.MDPI AG.* 2017;18(6). doi:10.3390/ijms18061257
21. Zhao X, Zuo X, Zhong J, et al. Heparin-Modified Amniotic Membrane Combined With Growth Factors for Promoting Corneal Wound Healing After Alkali Burn. *Front Bioeng Biotechnol.* 2020;8. doi:10.3389/fbioe.2020.599800
22. Smith R, John S, Nishina P, Sundberg J. *Systematic Evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods*. 1st ed. CRC Press; 2002.
23. Cade F, Paschalis EI, Regatieri C V, Vavvas DG, Dana R, Dohlman CH. *Alkali Burn to the Eye: Protection Using TNF- α Inhibition.*; 2014. www.corneajrnl.com
24. Guliás-Cañizo R, Lagunes-Guillén A, González-Robles A, Sánchez-Guzmán E, Castro-Muñozledo F. (-)-Epigallocatechin-3-gallate, reduces corneal damage secondary from experimental grade II alkali burns in mice. *Burns.* 2019;45(2):398-412. doi:10.1016/j.burns.2018.08.021
25. Paschalis EI, Zhou C, Lei F, et al. Mechanisms of Retinal Damage after Ocular Alkali Burns. *American Journal of Pathology.* 2017;187(6):1327-1342. doi:10.1016/j.ajpath.2017.02.005
26. Kethiri AR, Singh VK, Damala M, et al. Long term observation of ocular surface alkali burn in rabbit models: Quantitative analysis of corneal haze,

- vascularity and self-recovery. *Exp Eye Res.* 2021;205. doi:10.1016/j.exer.2021.108526
27. Singh P, Tyagi M, Kumar Y, Gupta K, Sharma P. Ocular chemical injuries and their management. *Oman J Ophthalmol.* 2013;6(2):83-86. doi:10.4103/0974-620X.116624
 28. Akgun Z, Selver OB. Epidemiology and etiology of chemical ocular injury: A brief review. *World J Clin Cases.* 2023;11(6):1245-1251. doi:10.12998/wjcc.v11.i6.1245
 29. Bizrah M, Yusuf A, Ahmad S. An update on chemical eye burns. *Eye (Basingstoke).Nature Publishing Group.* 2019;33(9):1362-1377. doi:10.1038/s41433-019-0456-5
 30. Hammadi F, Himayani R, Ristyaning P, Sangging A. *LITERATURE REVIEW: TRAUMA KIMIA OKULAR DAN PENATALAKSAAANNYA.* Vol 10.; 2023. <http://ejurnalmalahayati.ac.id/index.php/kesehatan>
 31. Judkins D, Chen R, McTeer A. Alkali Toxicity. In: *NCBI Bookshelf. A Service of the National Library of Medicine, National Institutes of Health.* StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. <https://www.ncbi.nlm.nih.gov/books/NBK544235/?report=printable>
 32. Eslani M, Baradaran-Rafii A, Movahedan A, Djalilian AR. The ocular surface chemical burns. *J Ophthalmol.Hindawi Publishing Corporation.* 2014;2014. doi:10.1155/2014/196827
 33. Patek GC, Bates A, Affiliations AZ. Ocular Burns. In: *NCBI Bookshelf. A Service of the National Library of Medicine, National Institutes of Health.* StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. <https://www.ncbi.nlm.nih.gov/books/NBK459221/?report=printable>
 34. Wang P, Hao P, Chen X, et al. Targeting HMGB1-NF κ b Axis and miR-21 by Glycyrrhizin: Role in Amelioration of Corneal Injury in a Mouse Model of Alkali Burn. *Front Pharmacol.* 2022;13. doi:10.3389/fphar.2022.841267
 35. Sprogyte L, Park M, Di Girolamo N. Pathogenesis of Alkali Injury-Induced Limbal Stem Cell Deficiency: A Literature Survey of Animal Models. *Cells.MDPI.* 2023;12(9). doi:10.3390/cells12091294
 36. Mashige K. Chemical and thermal ocular burns: A review of causes, clinical features and management protocol. *South African Family Practice.Medpharm Publications.* 2016;58(1):1-4. doi:10.1080/20786190.2015.1085221
 37. Hamill CE, Bozorg S, Chang HYP, et al. *Corneal Alkali Burns: A Review of the Literature and Proposed Protocol for Evaluation and Treatment.* www.internat-ophthalmology.com
 38. Banayot R, Swaiti Y, Al-hashash I. Acute ocular chemical injury: a descriptive assessment and management review at St. John Eye Hospital, Jerusalem, Palestine. *Ophthalmology Journal.* 2021;6(0):171-177. doi:10.5603/oj.2021.0032

39. Kempuraj D, Mohan RR. Autophagy in Extracellular Matrix and Wound Healing Modulation in the Cornea. *Biomedicines.MDPI*. 2022;10(2). doi:10.3390/biomedicines10020339
40. Hakami NY, Dusting GJ, Chan EC, Shah MH, Peshavariya HM. Wound Healing after Alkali Burn Injury of the Cornea Involves Nox4-Type NADPH Oxidase. *Invest Ophthalmol Vis Sci*. 2020;61(12). doi:10.1167/IOVS.61.12.20
41. Willmann D, Fu L, Melanson SW. Corneal Injury. In: *NCBI Bookshelf. A Service of the National Library of Medicine, National Institutes of Health*. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025; 2025. <https://www.ncbi.nlm.nih.gov/books/NBK459283/?report=printable>
42. Fortingo N, Melnyk S, Sutton SH, Watsky MA, Bollag WB. Innate Immune System Activation, Inflammation and Corneal Wound Healing. *Int J Mol Sci.MDPI*. 2022;23(23). doi:10.3390/ijms232314933
43. Yi Q, Zou WJ. The Wound Healing Effect of Doxycycline after Corneal Alkali Burn in Rats. *J Ophthalmol*. 2019;2019. doi:10.1155/2019/5168652
44. Liu T, Zhang L, Joo D, Sun SC. NF- κ B signaling in inflammation. *Signal Transduct Target Ther.Springer Nature*. 2017;2. doi:10.1038/sigtrans.2017.23
45. Liang W, Zhang Y, Zhou L, et al. Zeb1 regulation of wound-healing-induced inflammation in alkali-damaged corneas. *iScience*. 2022;25(4). doi:10.1016/j.isci.2022.104038
46. Yu Q, Biswas S, Ma G, Zhao P, Li B, Li J. Canonical nf-kb signaling maintains corneal epithelial integrity and prevents corneal aging via retinoic acid. *Elife*. 2021;10. doi:10.7554/eLife.67315
47. Russo C, Rusciano D, Santangelo R, Malaguarnera L. Options for Topical Treatment of Oxidative Eye Diseases with a Special Focus on Retinopathies. *Medicina (Lithuania).Multidisciplinary Digital Publishing Institute (MDPI)*. 2024;60(3). doi:10.3390/medicina60030354
48. Pei Y, Liu H, Yang Y, et al. Biological activities and potential oral applications of N-acetylcysteine: Progress and prospects. *Oxid Med Cell Longev.Hindawi Limited*. 2018;2018. doi:10.1155/2018/2835787
49. Messina M, Dua HS. Early results on the use of chitosan-N-acetylcysteine (Lacrimera ®) in the management of dry eye disease of varied etiology. *Int Ophthalmol*. 2019;39(3):693-696. doi:10.1007/s10792-018-0843-0
50. Akyol-Salman Í, Azizi S, Mumcu U, Baykal O. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. *Journal of Ocular Pharmacology and Therapeutics*. 2010;26(4):329-333. doi:10.1089/jop.2010.0001
51. Tsai ML, Huang HP, Hsu JD, et al. Topical N-acetylcysteine accelerates wound healing in vitro and in vivo via the PKC/Stat3 pathway. *Int J Mol Sci*. 2014;15(5):7563-7578. doi:10.3390/ijms15057563

52. Mohan RR, Kempuraj D, D'Souza S, Ghosh A. Corneal stromal repair and regeneration. *Prog Retin Eye Res.* 2022;91:101090. doi:10.1016/j.preteyeres.2022.101090
53. Nakano Y, Uchiyama M, Arima T, et al. PPAR α Agonist Suppresses Inflammation after Corneal Alkali Burn by Suppressing Proinflammatory Cytokines, MCP-1, and Nuclear Translocation of NF- κ B. *Molecules.* 2018;24(1):114. doi:10.3390/molecules24010114
54. Kubota M, Shimmura S, Kubota S, et al. Hydrogen and N-acetyl-L-cysteine rescue oxidative stress-induced angiogenesis in a mouse corneal alkali-burn model. *Investigative Ophthalmology & Visual Science.* 2011;52(1):427. doi:10.1167/iovs.10-6167
55. Khoshdel AR, Emami Aleagha O, Shahriary A, Aghamollaei H, Najjar Asiabani F. Topical Effects of N-Acetyl Cysteine and Doxycycline on Inflammatory and Angiogenic Factors in the Rat Model of Alkali-Burned Cornea. *Journal of Interferon & Cytokine Research.* 2022;42(2):82-89. doi:10.1089/jir.2021.0150
56. Ramaesh T, Ramaesh K, Riley SC, West JD, Dhillon B. Effects of N-acetylcysteine on matrix metalloproteinase-9 secretion and cell migration of human corneal epithelial cells. *Eye.* 2012;26(8):1138-1144. doi:10.1038/eye.2012.135
57. Lingappan K. NF- κ B in oxidative stress. *Curr Opin Toxicol.* 2018;7:81-86. doi:10.1016/j.cotox.2017.11.002
58. Dammak A, Pastrana C, Martin-Gil A, et al. Oxidative Stress in the Anterior Ocular Diseases: Diagnostic and Treatment. *Biomedicines.* 2023;11(2):292. doi:10.3390/biomedicines11020292
59. Montero P, Roger I, Estornut C, Milara J, Cortijo J. Influence of dose and exposition time in the effectiveness of N-Acetyl-L-cysteine treatment in A549 human epithelial cells. *Heliyon.* 2023;9(5):e15613. doi:10.1016/j.heliyon.2023.e15613
60. Sekundo W, Augustin AJ, Strempel I. Topical Allopurinol or Corticosteroids and Acetylcysteine in the Early Treatment of Experimental Corneal Alkali Burns: A Pilot Study. *Eur J Ophthalmol.* 2002;12(5):366-372. doi:10.1177/112067210201200504
61. Stachura A, Sobczak M, Kędra K, Kopka M, Kopka K, Włodarski PK. The Influence of N-Acetylcysteine-Enriched Hydrogels on Wound Healing in a Murine Model of Type II Diabetes Mellitus. *Int J Mol Sci.* 2024;25(18):9986. doi:10.3390/ijms25189986
62. Sohani Z, Jamshidi S, Koochi MK, et al. Novel ophthalmic hyaluronic acid-hydrogel with curcumin nanoparticles for enhanced healing of ulcerative keratitis in rabbit model. *Sci Rep.* 2024;14(1):23046. doi:10.1038/s41598-024-74195-w

63. Guo Q, Jin Y, Chen X, et al. NF- κ B in biology and targeted therapy: new insights and translational implications. *Signal Transduct Target Ther.* 2024;9(1):53. doi:10.1038/s41392-024-01757-9
64. Soleimani M, Naderan M. Management Strategies of Ocular Chemical Burns: Current Perspectives. *Clinical Ophthalmology.* 2020;Volume 14:2687-2699. doi:10.2147/OPTH.S235873
65. Maghsadi Z, Azadmehr A, Moghadamnia AA, Feizi F, Hamidi N. N-Acetylcysteine attenuated pulmonary fibrosis induced by bleomycin via immunomodulation responses. *Res Pharm Sci.* 2023;18(2):177-184. doi:10.4103/1735-5362.367796
66. Gonciar D, Berciu AG, Danku AE, et al. The Quantification of Myocardial Fibrosis on Human Histopathology Images by a Semi-Automatic Algorithm. *Applied Sciences.* 2024;14(17):7696. doi:10.3390/app14177696
67. Amin AH, El Missiry MA, Elhusseini FM, Mutawi TM. Assessment of Hepatic Fibrosis by Image Analysis Software in relation to Physiological Markers. *Int J Adv Res (Indore).* 2016;4(4):1676-1688. doi:10.21474/IJAR01/223
68. Zakaria AY, Badawi R, Osama H, Abdelrahman MA, El-Kalaawy AM. A Comparative Study of N-Acetyl Cysteine, Rosuvastatin, and Vitamin E in the Management of Patients with Non-Alcoholic Steatohepatitis: A Randomized Controlled Trial. *Pharmaceuticals.* 2025;18(5):650. doi:10.3390/ph18050650
69. Har-Zahav A, Tobar A, Fried S, et al. Oral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice. *Sci Rep.* 2024;14(1):26513. doi:10.1038/s41598-024-78387-2
70. Tang M, Yang Z, Liu J, et al. Combined intervention with N-acetylcysteine and desipramine alleviated silicosis development by regulating the Nrf2/HO-1 and ASMase/ceramide signaling pathways. *Ecotoxicol Environ Saf.* 2022;242:113914. doi:10.1016/j.ecoenv.2022.113914
71. DiNicolantonio JJ, McCarty MF, Barroso-Aranda J, Assanga S, Lujan LML, O'Keefe JH. A nutraceutical strategy for downregulating TGF β signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis. *Open Heart.* 2021;8(1):e001663. doi:10.1136/openhrt-2021-001663
72. Ghafouri-Fard S, Askari A, Shoorei H, et al. Antioxidant therapy against TGF- β / SMAD pathway involved in organ fibrosis. *J Cell Mol Med.* 2024;28(2). doi:10.1111/jcmm.18052